Introduction {#s1}
============

In early 2020, coronavirus disease 2019 (COVID-19), which arises from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has been the world\'s largest health crisis ([@B1], [@B2]). SARS-CoV-2 is rapidly spreading around the world and infected more than 4000,000 people worldwide as of May 16th 2020 ([@B1], [@B3], [@B4]). According to the coronavirus guidelines, the disease is generally classified into 4 types: mild, moderate, severe, and critical ([@B5]). Zhang reported that mild or moderate patients accounted for more than 80% of patients with COVID-19 ([@B6]). The severe and critical patients usually require more attention due to the poor outcomes, according to previous reports ([@B7]). However, the clinical characteristics and prognostic factors of mild-moderate patients have rarely been reported. In addition, these mild or moderate patients should be admitted to the hospital to prevent progression of the disease and should be isolated from susceptible populations to prevent further transmission. However, the limited capacity of designated hospitals for infectious disease patients makes the prevention and treatment of COVID-19 challenging.

Mobile cabin hospitals, generally composed of medical treatment units, ward units, technical support units, and others, are a type of modular health equipment with emergency treatment, surgical treatment, clinical testing, and other functions and are widely used in a variety of emergency treatment scenarios, the military field, and other fields ([@B8]). During the past infectious disease epidemics or natural disasters, mobile cabin hospitals have been put in place to cope with the shortage of medical sources ([@B9], [@B10]). However, the capacity of the hospital is limited. Compared to the traditional mobile hospitals, novel mobile cabin hospitals (also named as Fangcang hospitals in China) could provide many more medical beds in a short time. In Wuhan, several novel mobile cabin hospitals were transformed from large public facilities such as sports stadium and exhibition center in a very short time, providing thousands of beds to admit and treat mild-to-moderate COVID-19 patients. If condition worsening occurred, patients were transferred to a nearby designated hospital for critical patients.

In this study, we aimed to describe the clinical characteristics and outcomes of 869 hospitalized mild-moderate patients from Wuchang Mobile Cabin Hospital and compared the clinical findings of patients with COVID-19 stratified according to sex, age, comorbidity, and time of diseases onset.

Methods {#s2}
=======

Study Design and Participants
-----------------------------

This was a retrospective study. The study involving human participants was reviewed and approved by the Institutional Ethics Board of Renmin Hospital of Wuhan University. Written informed consent from the participants\' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements. During the period of February 6th, 2020 to February 20th, 2020, 869 confirmed hospitalized cases of SARS-CoV2 admitted to Wuchang Mobile Cabin Hospital were enrolled in this study. The diagnosis of COVID-19 was made according to the Diagnosis and Treatment of Pneumonia Infected by Novel Coronavirus (5th trial edition) published by the General Office of the National Health Commission and the General Office of the National Administration of Traditional Chinese Medicine ([@B11]).

According to the Diagnosis and Treatment of Pneumonia Infected by Novel Coronavirus (5th trial edition), all of the recruited patients were classified as mild-moderate on admission. The detail criterion ([@B11]) for clinical classification: Mild: mild signs or symptoms, imaging shows no signs of pneumonia; Moderate: fever, respiratory tract symptoms, imaging shows pneumonia; Severe: satisfy any of the following: (1) respiratory distress, respiratory rate ≥30 beats per minute; (2) SpO~2~ ≤ 93% at resting; (3) arterial PaO~2~/FiO~2~ ≤ 300 mmHg; Critical: satisfy any of the following: (1) respiratory failure, need mechanical ventilation; (2) shock; (3) combined with other organ failure, requiring intensive care. The onset of disease was defined as the time of the first occurrence of related symptoms.

The outcome information of these patients was collected until March 6th, 2020, including remaining in the mobile cabin hospital, discharged, and transferred to the designated hospital for critical patients due to worsening of the patient\'s condition. The worsening of the condition of patients may have been due to COVID-19 or basic diseases. To be specific, if patients met any of the following criteria ([@B12]), they were quickly transferred to the designated higher-level hospitals: (1) met the criterion of severe or critical; (2) lung imaging showing a greater than 50% progression of lesions within 24--48 h; (3) development of basic disease, such as hypertension, diabetes, coronary artery disease, etc. To compare the outcomes of patients by stratification according to the onset time of diseases, we analyzed information within 15 days of admission.

Data Collection
---------------

The clinical data (including basic information, clinical symptoms and signs, history, comorbidities, treatment and outcomes) were obtained by experienced clinicians based on the medical records system of the hospital. Manifestations on computed tomography (CT) were summarized by integrating the documentation or description in medical charts.

Grouping According to Different Factors
---------------------------------------

Sex was classified as male or female. Since 99.7% of patients were less than 70 years, age was classified into three groups according to the population distribution: \<45, 45--60, and \>60 years. Comorbidities were determined based on the patient\'s self-report on admission and were initially treated as a categorical variable (yes vs. no). Onset time was classified into four groups based on the integration of time and population descriptions as follows: Period 1, January 16th to January 25th, 2020; Period 2, January 26th to January 31st, 2020; Period 3, February 1st to February 6th, 2020; and Period 4, February 7th to February 14th, 2020. Patients with unclear onset information were excluded from the onset time cohorts.

Statistical Analysis
--------------------

Statistical analyses were conducted with SPSS software version 22.0 (Chicago, USA) and EmpowerStats software. The continuous variables are expressed as the median and interquartile range (IQR), and the differences between any two groups were determined by the Mann-Whitney test. The categorical variables are presented as counts (percentages) and were compared with chi-square tests, although Fisher\'s exact test was used when the data were limited. The Kaplan-Meier test was used to compare the cumulative risk rate. Cox proportional hazard regression models and landmark analysis were applied to identify the potential risk factors associated with the endpoint as appropriate, with the hazard ratio (HR) and 95% confidence interval (95% CI) being reported.

Results {#s3}
=======

Clinical Characteristics and Outcomes of All Patients Treated in Novel Mobile Cabin Hospitals
---------------------------------------------------------------------------------------------

Our database included 869 cases from Wuchang Mobile Cabin Hospital. Of these 869 cases, the median age was 52 years. A total of 377 patients (377/869; 43.4%) were males. A total of 121 patients (121/869; 13.9%) reported having at least one comorbidity, and 24 patients (24/869; 2.8%) had more than one comorbidity. The most common symptom was fever (565/869; 65%), followed by cough (424/869; 48.8%), fatigue (226/869; 26.0%), anorexia (216/869; 24.9%), and muscle aches (114/869; 13.1%). However, only 22 patients (22/839; 2.6%) had fever when vital signs were checked at admission, and the percent of patients showed the highest temperature \> 37.3°C during hospital was only 7.2% (60/839), indicating that simple temperature screening may have limited effect in public. Ninety-one percent of patients showed a manifestation of pneumonia on lung CT, although some patients\' lung CT scans were unavailable. The vast majority of patients (845/869; 97.2%) were treated with antiviral drugs, and all patients (100%) were treated with traditional Chinese medicine. Ultimately, 616 patients (616/869; 70.9%) were discharged from the novel mobile cabin hospital through March 6th, 2020. Ninety-five patients (95/869; 10.9%) reached the endpoint (transferred to the designated hospital for critical patients), and 158 patients (158/869; 18.2%) were still in the hospital. All data are shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics and outcomes of total, male and female patients in mobile cabin hospital.

                                                    **All (*n* = 869)**   **Male (*n* = 377)**   **Female (*n* = 492)**   ***P*-value**
  ------------------------------------------------- --------------------- ---------------------- ------------------------ ---------------
  **Age, median (IQR), years**                      51 (40, 58)           48 (38, 57)            52 (42, 59)              \<0.001\*
  **Comorbidity, No. (%)**                          121 (13.9)            53 (14.1)              68 (13.8)                0.920
  Diabetes                                          21 (2.4)              7 (1.9)                14 (2.8)                 0.347
  Hypertension                                      91 (10.5)             45 (11.9)              46 (9.3)                 0.217
  Coronary heart disease                            5 (0.6)               2 (0.5)                3 (0.6)                  1
  COPD/asthma                                       11 (1.3)              2 (0.5)                9 (1.8)                  0.164
  Cerebrovascular disease                           1 (0.1)               0                      1 (0.2)                  1
  Chronic renal disease                             4 (0.5)               3 (0.8)                1 (0.2)                  0.439
  Chronic liver disease                             5 (0.6)               2 (0.5)                3 (0.6)                  1
  Malignancy                                        6 (0.7)               1 (0.3)                5 (1.0)                  0.362
  Single comorbidity                                97 (11.2)             44 (11.7)              53 (10.8)                0.677
  ≥2 comorbidities                                  24 (2.8)              9 (2.4)                15 (3.0)                 0.555
  **Symptoms, No. (%)**                                                                                                   
  Fever                                             565 (65.0)            258 (68.4)             307 (62.4)               0.064
  Symptoms of respiratory system                    494 (56.8)            202 (53.6)             292 (59.3)               0.089
   Sore throat                                      18 (2.1)              5 (1.3)                13 (2.6)                 0.177
   Cough                                            424 (48.8)            183 (48.5)             241 (49.0)               0.897
   Expectoration                                    36 (4.1)              17 (4.5)               19 (3.9)                 0.635
   Chest tightness                                  104 (12.0)            25 (6.6)               79 (16.1)                \<0.001\*
   Chest pain                                       13 (1.5)              5 (1.3)                8 (1.6)                  0.718
   Dyspnea                                          47 (5.4)              13 (3.4)               34 (6.9)                 0.025\*
  Catarrhal symptoms                                14 (1.6)              7 (1.9)                7 (1.4)                  0.615
  Symptoms of nervous and muscle system             258 (29.7)            120 (31.8)             138 (28.0)               0.227
   Fatigue                                          226 (26.0)            113 (30.0)             113 (23.0)               0.02\*
   Dizziness                                        12 (1.4)              2 (0.5)                10 (2.0)                 0.06
   Headache                                         18 (2.1)              4 (1.1)                14 (2.8)                 0.067
   Muscle ache                                      114 (13.1)            70 (18.6)              44 (8.9)                 \<0.001\*
  Symptoms of alimentary system                     269 (31.0)            135 (35.8)             134 (27.2)               0.007\*
   Anorexia                                         216 (24.9)            122 (32.4)             94 (19.1)                \<0.001\*
   Nausea                                           18 (2.1)              5 (1.3)                13 (2.6)                 0.177
   Vomiting                                         16 (1.8)              5 (1.3)                11 (2.2)                 0.323
   Diarrhea                                         58 (6.7)              18 (4.8)               40 (8.1)                 0.049\*
  **Signs on admission, median (IQR)**                                                                                    
  Temperature, °C                                   36.5 (36.3, 36.7)     36.5 (36.3, 36.7)      36.5 (36.3, 36.7)        
   \>37.3, No. (%)*^a^*                             22 (2.6)              11 (3.1)               11 (2.3)                 
  Heart rate, bpm                                   81 (74, 90)           82 (74, 92)            80 (75, 89)              0.047\*
  Finger oxygen saturation, %                       97 (96, 98)           97 (96, 98)            97 (96, 98)              0.237
  Respiratory rate, bpm                             20 (18, 21)           20 (18, 21)            20 (18, 20)              0.586
  **Highest temperature during hospital**, **°C**                                                                         
   \>37.3, No. (%)*^a^*                             60 (7.2)              33 (9.2)               27 (5.6)                 0.06
  **Characteristics of lung CT, No. (%)**^**b**^                                                                          
  Pneumonia                                         424 (91.0)            173 (90.6)             251 (91.3)               0.796
   Unilateral lung                                  50 (10.7)             22 (11.5)              28 (10.2)                0.647
   Bilateral lung                                   374 (80.3)            151 (79.1)             223 (81.1)               0.588
   Ground-glass opacity                             339 (72.7)            147 (77.0)             192 (69.8)               0.088
   Reticular/linear                                 220 (47.2)            101 (52.9)             119 (43.3)               0.041\*
   Air bronchogram                                  9 (1.9)               7 (3.7)                2 (0.7%)                 0.054
   Consolidation shadow                             22 (4.7)              13 (6.8)               9 (3.3)                  0.077
  **Medical treatment, No. (%)**                                                                                          
  Antiviral treatment                               845 (97.2)            365 (96.8)             480 (97.6)               0.507
  Traditional Chinese medicine                      869 (100)             377 (100)              492 (100)                1
  **Outcome, No. (%)**                                                                                                    
  Discharge from mobile cabin hospital              616 (70.9)            266 (70.6)             350 (71.1)               0.852
  Transfer to the designated hospital               95 (10.9)             42 (11.1)              53 (10.8)                0.863
  Staying in mobile cabin hospital                  158 (18.2)            69 (18.3)              89 (18.1)                0.936

*The total number of patients with available data: a: total = 839, male = 358, female = 481; b: total = 466, male = 191, female = 275. COPD, chronic obstructive pulmonary disease; IQR, interquartile range. P-values indicate differences between male and female patients. \*indicates P-value \<0.05*.

Clinical Characteristics According to Sex
-----------------------------------------

Female patients were older than male patients (54 \[44, 61\] vs. 50 \[39, 59\], *p* \< 0.001). Male patients were more likely to have fatigue (113/377, 30% vs. 113/492, 23%, *p* = 0.02), muscle aches (70/377, 18.6% vs. 44/4928.9%, *p* \< 0.001), and anorexia (122/377, 32.4% vs. 94/492, 19.1%, *p* \< 0.001). Female patients were more likely to have chest tightness (79/492, 16.1% vs. 25/377, 6.6%, *p* \< 0.001), dyspnea (34/492, 6.9% vs. 13/377, 3.4%, *p* = 0.025), and diarrhea (40/492, 8.1% vs. 18/377, 4.8%, *p* = 0.049). Male patients were more likely to have reticular/linear manifestations (101/191, 52.9% vs. 119/275, 43.3%, *p* = 0.041) on lung CT, although no significant differences were observed in other features. The results may suggest that the conditions of male patients were possibly worse than those of females. However, there were no differences in outcomes between male patients and female patients. The data are shown in [Table 1](#T1){ref-type="table"}.

Clinical Characteristics According to Age
-----------------------------------------

Age was classified into three groups: \<45 years (*n* = 323), 45--60 years (*n* = 378) and \>60 years (*n* = 168). The group of older patients included fewer male patients than the group of younger patients (65/168, 38.7% vs. 144/378, 38.1% vs. 168/323, 52%). The group of older patients included more patients with at least one comorbidity (41/168, 24.4% vs. 64/378, 16.9% vs. 16/323, 5%), more patients with a single comorbidity (33/168, 19.6% vs. 50/378, 13.2% vs. 14/323, 4.3%) and more patients with two or more comorbidities (8/168, 4.8% vs. 14/378, 3.7% vs. 2/323, 0.6%). Conversely, fewer older patients had fever (101/168, 60.1% vs. 247/378, 65.3%, vs. 217/323, 67.2%) than younger patients, although the differences were not significant. In addition, older patients had lower heart rates and oxygen saturation on admission. CT results found that both the \>60-year group and the 45- to 60-year group included more patients with pneumonia manifestations (97/99, 98% vs. 200/214, 93.5% vs. 127/153, 83%), which were more complex in the two older groups. Discharged patients were more commonly aged less than 45 than \>60 years (244/323, 75.5% vs. 107/168, 63.7%). Both the \>60-year group and the 45- to 60-year group had more patients (23/168, 13.7% vs. 51/378, 13.5% vs. 21/323, 6.5%) transferred to the designated hospital due to worsening condition, although significant differences between the \>65-year group and the 45 to 60-year group were not observed. All data are shown in [Table 2](#T2){ref-type="table"}.

###### 

Characteristics and outcomes of patients with different ages.

                                                    **Age, years**                          
  ------------------------------------------------- ------------------- ------------------- -------------------
  **Sex, No. (%)**                                                                          
   Male                                             168 (52.0)          144 (38.1)\*        65 (38.7)\*
   Female                                           155 (48.0)          234 (61.9)          103 (61.3)
  **Comorbidity, No. (%)**                          16 (5.0)            64 (16.9)\*         41 (24.4)\*\#
  Diabetes                                          4 (1.2)             9 (2.4)             8 (4.8)\*
  Hypertension                                      10 (3.1)            52 (13.8)\*         29 (17.3)\*
  Coronary heart disease                            0                   3 (0.8)             2 (1.2)
  COPD/asthma                                       2 (0.6)             7 (1.9)             2 (1.2)
  Cerebrovascular disease                           0                   0                   1 (0.6)
  Chronic renal disease                             0                   2 (0.5)             2 (1.2)
  Chronic liver disease                             1 (0.3)             3 (0.8)             1 (0.6)
  Malignancy                                        1 (0.3)             2 (0.5)             3 (1.8)
  Single comorbidity                                14 (4.3)            50 (13.2)\*         33 (19.6)\*
  ≥2 comorbidities                                  2 (0.6)             14 (3.7)\*          8 (4.8)\*
  **Symptoms, No. (%)**                                                                     
  Fever                                             217 (67.2)          247 (65.3)          101 (60.1)
  Symptoms of respiratory system                    186 (57.6)          223 (59.0)          85 (50.6)
   Sore throat                                      10 (3.1)            8 (2.1)             0\*
   Cough                                            161 (49.8)          186 (49.2)          77 (45.8)
   Expectoration                                    16 (5.0)            16 (4.2)            4 (2.4)
   Chest tightness                                  31 (9.6)            58 (15.3)\*         15 (8.9)\#
   Chest pain                                       6 (1.9)             7 (1.9)             0
   Dyspnea                                          12 (3.7)            23 (6.1)            12 (7.1)
  Catarrhal symptoms                                7 (2.2)             5 (1.3)             2 (1.2)
  Symptoms of nervous and muscle system             89 (27.6)           110 (29.1)          59 (35.1)
   Fatigue                                          77 (23.8)           97 (25.7)           52 (31.0)
   Dizziness                                        6 (1.9)             5 (1.3)             1 (0.6)
   Headache                                         7 (2.2)             7 (1.9)             4 (2.4)
   Muscle ache                                      49 (15.2)           42 (11.1)           23 (13.7)
  Symptoms of alimentary system                     96 (29.7)           122 (32.3)          51 (30.4)
   Anorexia                                         82 (25.4)           91 (24.1)           43 (25.6)
   Nausea                                           3 (0.9)             12 (3.2)\*          3 (1.8)
   Vomiting                                         4 (1.2)             9 (2.4)             3 (1.8)
   Diarrhea                                         20 (6.2)            28 (7.4)            10 (6.0)
  **Signs on admission, median (IQR)**                                                      
  Temperature, °C                                   36.5 (36.3, 36.7)   36.5 (36.3, 36.7)   36.5 (36.3, 36.7)
  Heart rate, bpm                                   82 (75, 92)         81 (75, 89)         80 (73, 89)
  Finger oxygen saturation, %                       97 (96, 98)         97 (96, 98)\*       97 (96, 98)\*
  Respiratory rate, bpm                             18 (20, 20)         18 (20, 20)         18 (20, 21)
  **Highest temperature during hospital**, **°C**                                           
   \>37.3, No. (%)^a^                               25 (8.0)            46 (12.6)\*         12 (7.4)
  **Characteristics of lung CT, No. (%)**^**b**^                                            
  Pneumonia                                         127 (83.0)          200 (93.5)\*        97 (98.0)\*
   Unilateral lung                                  20 (13.1)           21 (9.8)            9 (9.1)
   Bilateral lung                                   107 (69.9)          179 (83.6)\*        88 (88.9)\*
   Ground-glass opacity                             101 (66.0)          163 (76.2)\*        75 (75.8)
   Reticular/linear                                 51 (33.3)           109 (50.9)\*        60 (60.6)\*
   Air bronchogram                                  2 (1.3)             6 (2.8)             1 (1.0)
   Consolidation shadow                             4 (2.6)             15 (7.0)            3 (3.0)
  **Medical treatment, No. (%)**                                                            
  Antiviral treatment                               314 (97.2)          372 (98.4)          160 (95.2)
  Traditional Chinese medicine                      323 (100)           378 (100)           168 (100)
  **Outcome, No. (%)**                                                                      
  Discharge from mobile cabin hospital              244 (75.5)          265 (70.1)          107 (63.7)\*
  Transfer to the designated hospital               21 (6.5)            51 (13.5)\*         23 (13.7)\*
  Staying in mobile cabin hospital                  58 (18.0)           62 (16.4)           38 (22.6)

*99.7% of patients were less than 70 years. The total number of patients with available data: a: \<45 years = 313, 45--60 years = 364, \>60 years = 162; b: \<45 years = 153, 45--60 years = 214, \>60 years = 99. COPD, chronic obstructive pulmonary disease; IQR, interquartile range. patients. \*p \< 0.05 vs. \<45 years group. ^\#^p \< 0.05 vs. 45--60 years group*.

Clinical Characteristics According to Comorbidity
-------------------------------------------------

Of the 869 cases, 121 patients (121/869; 13.9%) were reported to have at least one comorbidity. The most common comorbidities included hypertension (91/869; 10.5%), diabetes (21/869; 2.4%) and COPD/asthma (11/869; 1.6%) ([Table 1](#T1){ref-type="table"}). Patients with at least one comorbidity were older (median: 59 vs. 51 years, *p* \< 0.001). Of the patients who were transferred to the designated hospital for further treatment, there were more patients with at least one comorbidity than without (23/121, 19% vs. 72/748, 9.6%, *p* = 0.002). No significant differences were observed in the discharged patients between the two groups ([Table 3](#T3){ref-type="table"}).

###### 

Characteristics and outcomes of patients with or without any comorbidity.

                                                                  **Any comorbidity**                       
  --------------------------------------------------------------- --------------------- ------------------- -----------
  **Age, median (IQR), years**                                    49 (39, 58)           57 (51, 62)         \<0.001\*
  **Sex, No. (%)**                                                                                          
   Male                                                           324 (43.3)            53 (43.8)           0.920
   Female                                                         424 (56.7)            68 (56.2)           
  **Symptoms, No. (%)**                                                                                     
  Fever                                                           481 (64.3)            84 (69.4)           0.274
  Symptoms of respiratory system                                  416 (55.6)            78 (64.5)           0.068
   Sore throat                                                    18 (2.4)              0                   0.167
   Cough                                                          359 (48.0)            65 (53.7)           0.243
   Expectoration                                                  31 (4.1)              5 (4.1)             0.995
   Chest tightness                                                89 (11.9)             15 (12.4)           0.876
   Chest pain                                                     11 (1.5)              2 (1.7)             1
   Dyspnea                                                        38 (5.1)              9 (7.4)             0.287
  Catarrhal symptoms                                              10 (1.3)              4 (3.3)             0.227
  Symptoms of nervous and muscle system                           218 (29.1)            40 (33.1)           0.382
   Fatigue                                                        192 (25.7)            34 (28.1)           0.572
   Dizziness                                                      10 (1.3)              2 (1.7)             1
   Headache                                                       17 (2.3)              1 (0.8)             0.443
   Muscle ache                                                    102 (13.6)            12 (9.9)            0.261
  Symptoms of alimentary system                                   237 (31.7)            32 (26.4)           0.248
   Anorexia                                                       193 (25.8)            23 (19.0)           0.109
   Nausea                                                         15 (2.0)              3 (2.5)             1
   Vomiting                                                       15 (2.0)              1 (0.8)             0.596
   Diarrhea                                                       47 (6.3)              11 (9.1)            0.251
  **Signs on admission, median (IQR)**                                                                      
  Temperature, °C                                                 36.5 (36.3, 36.7)     36.5 (36.3, 36.7)   0.286
  Heart rate, bpm                                                 81 (75, 90)           79 (73, 88)         0.177
  Finger oxygen saturation, %                                     97 (96, 98)           97 (96, 98)         0.435
  Respiratory rate, bpm                                           20 (18, 21)           20 (18, 21)         0.904
  **Highest temperature during hospital, median (IQR)**, **°C**   36.9 (36.8, 37)       36.9 (36.8, 37.1)   0.677
  **Characteristics of lung CT, No. (%)***^***a***^*                                                        
  Pneumonia                                                       364 (90.5)            60 (93.8)           0.406
   Unilateral lung                                                37 (9.2)              13 (20.3)           0.008\*
   Bilateral lung                                                 327 (81.3)            47 (73.4)           0.14
   Ground-glass opacity                                           290 (72.1)            49 (76.6)           0.46
   Reticular/linear                                               185 (46.0)            35 (54.7)           0.197
   Air bronchogram                                                7 (1.7)               2 (3.1)             0.796
   Consolidation shadow                                           18 (4.5)              4 (6.3)             0.761
  **Medical treatment, No. (%)**                                                                            
  Antiviral treatment                                             725 (96.9)            120 (99.2)          0.271
  Traditional Chinese medicine                                    748 (100)             121 (100)           1
  **Outcome, No. (%)**                                                                                      
  Discharge from mobile cabin hospital                            533 (71.3)            83 (68.6)           0.55
  Transfer to the designated hospital                             72 (9.6)              23 (19.0)           0.002\*
  Staying in mobile cabin hospital                                143 (19.1)            15 (12.4)           0.075

*The total number of patients with available data: a: patients with comorbidities = 402, patients without = 64. COPD, chronic obstructive pulmonary disease; IQR, interquartile range. P-values indicate differences between patients with and without comorbidities. \*indicates P-value \< 0.05*.

Clinical Characteristics According to Onset Time of COVID-19
------------------------------------------------------------

The onset time cohorts were classified into four groups: Period 1, January 16th to January 25th, 2020 (*n* = 226); Period 2, January 26th to January 31st, 2020 (*n* = 235); Period 3, February 1st to February 6th, 2020 (*n* = 184); and Period 4, February 7th to February 14th, 2020 (*n* = 106). The incidence of the main symptoms, including fever (195/226, 86.3% vs. 186/235, 79.1% vs. 121/184, 65.8% vs. 54/106, 50.9%), cough (130/226, 57.5% vs. 147/235, 62.6% vs. 91/184, 49.5% vs. 44/106, 41.5%), fatigue (72/226, 31.9% vs. 80/235, 34% vs. 50/184, 27.2% vs. 20/106, 18.9%), muscle aches (31/226, 13.7% vs. 47/235, 20% vs. 28/184, 15.2% vs. 6/106, 5.7%), and anorexia (66/226, 29.2% vs. 88/235, 37.4% vs. 49/184, 26.6% vs. 10/106, 9.4%), decreased with time ([Figures 1A,B](#F1){ref-type="fig"}). The analyses of lung CT found that the period 4 group had fewer patients with pneumonia. The severity of CT manifestations was also decreasing, which was illustrated by the following items: rate of unilateral lung (5/123, 4.1% vs. 14/137, 10.2% vs. 16/106, 15.1% vs. 12/58, 20.7%), rate of bilateral lung (108/123, 87.8% vs. 118/137, 86.1% vs. 82/106, 77.4% vs. 36/58, 62.1%), and rate of ground-glass opacity (92/123, 74.8% vs. 106/137, 77.4% vs. 80/106, 75.5% vs. 36/58, 62.1%). However, there were no differences in the outcomes among the four groups within 15 days of admission. The data are shown in [Table 4](#T4){ref-type="table"}.

![Typical clinical symptoms of patient with COVID-19 showed a decreasing trend with time. X-axis indicates onset time of the disease. **(A)** fever and cough; **(B)** fatigue, anorexia, and muscle ache.](fpubh-08-00264-g0001){#F1}

###### 

Characteristics and outcomes of patients with different onset times.

                                                        **Period 1 (*n* = 226)**   **Period 2 (*n* = 235)**   **Period 3 (*n* = 184)**   **Period 4 (*n* = 106)**
  ----------------------------------------------------- -------------------------- -------------------------- -------------------------- --------------------------
  **Age, No. (IQR), years**                             52 (40, 60)                50 (39, 58)                52 (42, 59)                46 (38, 56)\*&
  **Sex, No. (%)**                                                                                                                       
   Male                                                 97 (42.9)                  89 (37.9)                  85 (46.2)                  49 (46.2)
   Female                                               129 (57.1)                 146 (62.1)                 99 (53.8)                  57 (53.8)
  **Comorbidity, No. (%)**                              32 (14.2)                  36 (15.3)                  28 (15.2)                  20 (18.9)
  Diabetes                                              8 (3.5)                    7 (3.0)                    3 (1.6)                    1 (0.9)
  Hypertension                                          22 (9.7)                   31 (13.2)                  19 (10.3)                  15 (14.2)
  Coronary heart disease                                1 (0.4)                    1 (0.4)                    1 (0.5)                    2 (1.9)
  COPD/asthma                                           3 (1.3)                    3 (1.3)                    4 (2.2)                    1 (0.9)
  Chronic renal disease                                 1 (0.4)                    1 (0.4)                    1 (0.5)                    1 (0.9)
  Chronic liver disease                                 2 (0.9)                    1 (0.4)                    0                          1 (0.9)
  Malignancy                                            1 (0.4)                    1 (0.4)                    3 (1.6)                    1 (0.9)
  Only one comorbidity                                  35 (15.5)                  27 (11.5)                  24 (13.0)                  18 (17.0)
  ≥2 comorbidity                                        7 (3.1)                    9 (3.8)                    4 (2.2)                    2 (1.9)
  **Symptoms, No. (%)**                                                                                                                  
  Fever                                                 195 (86.3)                 186 (79.1)\*               121 (65.8)\*\#             54 (50.9)\*\#&
  Symptoms of respiratory system                        150 (66.4)                 161 (68.5)                 108 (58.7)\#               60 (56.6)\#
   Sore throat                                          5 (2.2)                    4 (1.7)                    3 (1.6)                    5 (4.7)
   Cough                                                130 (57.5)                 147 (62.6)                 91 (49.5)\#                44 (41.5)\*\#
   Expectoration                                        14 (6.2)                   7 (3.0)                    9 (4.9)                    5 (4.7)
   Chest tightness                                      35 (15.5)                  32 (13.6)                  18 (9.8)                   17 (16.0)
   Chest pain                                           3 (1.3)                    0                          5 (2.7)\#                  4 (3.8)\#
   Dyspnea                                              14 (6.2)                   15 (6.4)                   12 (6.5)                   6 (5.7)
  Catarrhal symptoms                                    2 (0.9)                    4 (1.7)                    3 (1.6)                    4 (3.8)
  Symptoms of nervous and muscle system                 81 (35.8)                  90 (38.3)                  56 (30.4)                  27 (25.5)\#
   Fatigue                                              72 (31.9)                  80 (34.0)                  50 (27.2)                  20 (18.9)\*\#
   Dizziness                                            3 (1.3)                    4 (1.7)                    0                          4 (3.8)&
   Headache                                             7 (3.1)                    4 (1.7)                    5 (2.7)                    2 (1.9)
   Muscle ache                                          31 (13.7)                  47 (20.0)                  28 (15.2)                  6 (5.7)\*\#&
  Symptoms of alimentary system                         79 (35.0)                  107 (45.5)\*               62 (33.7)\#                18 (17.0)\*\#&
   Anorexia                                             66 (29.2)                  88 (37.4)                  49 (26.6)\#                10 (9.4)\*\#&
   Nausea                                               4 (1.8)                    8 (3.4)                    4 (2.2)                    2 (1.9)
   Vomiting                                             5 (2.2)                    7 (3.0)                    3 (1.6)                    1 (0.9)
   Diarrhea                                             14 (6.2)                   24 (10.2)                  13 (7.1)                   6 (5.7)
  **Signs on admission, median (IQR)**                                                                                                   
  Temperature, °C                                       36.5 (36.3, 36.7)          36.5 (36.3, 36.7)          36.5 (36.4, 36.7)          36.5 (36.3, 36.6)&
  Heart rate, bpm                                       81 (74, 90)                81 (75, 90)                79 (72, 89)                85 (76, 90)&
  Finger oxygen saturation, %                           97 (96, 98)                97 (96, 98)                97 (95, 98)\#              97 (96, 98)&
  Respiratory rate, bpm                                 20 (18, 21)                20 (18, 21)                20 (18, 20)                20 (19, 21)
  **Characteristics of lung CT, No. (%)***^***a***^*                                                                                     
  Pneumonia                                             113 (91.9)                 132 (96.4)                 98 (92.5)                  48 (82.8)\#
   Unilateral lung                                      5 (4.1)                    14 (10.2)                  16 (15.1)\*                12 (20.7)\*\#
   Bilateral lung                                       108 (87.8)                 118 (86.1)                 82 (77.4)\*                36 (62.1)\*\#&
   Ground-glass opacity                                 92 (74.8)                  106 (77.4)                 80 (75.5)                  36 (62.1)\#
   Reticular/linear                                     57 (46.3)                  63 (46.0)                  52 (49.1)                  23 (39.7)
   Air bronchogram                                      1 (0.8)                    3 (2.2)                    1 (0.9)                    1 (1.7)
   Consolidation shadow                                 3 (2.4)                    4 (2.9)                    7 (6.6)                    1 (1.7)
  **Medical treatment, No. (%)**                                                                                                         
  Antiviral treatment                                   223 (98.7)                 233 (99.1)                 181 (98.4)                 102 (96.2)
  Traditional chinese medicine                          226 (100)                  235 (100)                  184 (100)                  106 (100)
  **Outcome within 15 days after admission, No. (%)**                                                                                    
  Discharge from mobile cabin hospital                  110 (48.7)                 122 (51.9)                 82 (44.6)                  49 (46.2)
  Transfer to the designated hospital                   12 (5.3)                   7 (3.0)                    10 (5.4)                   6 (5.7)
  Staying in mobile cabin hospital                      104 (46.0)                 106 (45.1)                 92 (50.0)                  51 (48.1)

*Period 1: January 16th to January 25th, 2020; Period 2: January 26th to January 31st, 2020; Period 3: February 1st to February 6th, 2020; Period 4: February 7th to February 14th, 2020. The total number of patients with available data: a: Period 1 = 123, Period 2 = 137, Period 3 = 106, Period 4 = 58. COPD, chronic obstructive pulmonary disease; IQR, interquartile range. \*p \< 0.05 vs. Period 1; ^\#^p \< 0.05 vs. Period 2; ^&^p \< 0.05 vs. Period 3*.

Prognostic Analyses
-------------------

We defined transfer to a designated hospital as the endpoint. Patients aged 45 or older had significantly higher risks of reaching the endpoint than those younger than 45 years old (*p* \< 0.05) ([Figure 2A](#F2){ref-type="fig"}). Patients with at least one comorbidity also had significantly higher risks of reaching the endpoint than those without comorbidities (*p* \< 0.05) ([Figure 2B](#F2){ref-type="fig"}). After adjusting for comorbidities and sex, patients aged 45 or older were more likely to reach the endpoint than those younger than 45 years old (HR, 1.892, 95% CI, 1.154--3.102, *p* = 0.011) ([Figure 2C](#F2){ref-type="fig"}). After adjusting for age and sex, patients with comorbidities were more likely to reach the endpoint than those without comorbidities (HR, 2.733, 95% CI, 1.496--4.994, *p* = 0.001) ([Figure 2C](#F2){ref-type="fig"}) when staying in the mobile cabin hospital for more than 10 days. However, there were no significant differences between patients with or without comorbidities within 10 days of hospitalization ([Figure 2C](#F2){ref-type="fig"}).

![Comparison of the time-dependent risks and predictors of the endpoint. **(A)** The time-dependent risk of reaching to the endpoint between patients aged 45 or older (bottle green curve) and patients of less than 45 years (orange curve); **(B)** The time-dependent risk of reaching to the composite endpoints between patients with (red curve) or without any comorbidity (dark blue curve); **(C)** Shown in the figure are the hazards ratio (HR) and the 95% confidence interval (95% CI) for the risk factors associated with the endpoint (transferred to the designated hospitals for critical patients due to condition worsen). The scale bar indicates the HR. The model of age has been adjusted with gender and comorbidity. The model of comorbidity has been adjusted with gender and age.](fpubh-08-00264-g0002){#F2}

Since a total of 466 patients were available in lung CT reports. Therefore, we recruited these 466 patients in a new model to analyze the CT findings of prognostic value. The univariate proportion COX regress analysis found that several lung CT features (ground-glass opacity, reticular/linear, air bronchogram, and consolidation shadow) were associated with prognosis. The multivariate COX regression analysis indicated that ground-glass opacity (HR, 2.096, 95% CI, 1.102--3.985, *p* = 0.024), reticular/linear (HR, 2.07, 95% CI, 1.275--3.362, *p* = 0.003), air bronchogram (HR, 4.741, 95% CI, 1.869--12.029, *p* = 0.001), and consolidation shadow (HR, 8.994, 95% CI, 4.953--16.331, *p* \< 0.001) were associated with the poor outcome (transfer to the designated high-level hospitals due to condition worsen) for mild-moderate COVID-19 patients. The multivariate COX regression model has adjusted age, sex, and comorbidity ([Table 5](#T5){ref-type="table"}).

###### 

The effect of chest CT on the prognosis of mild-moderate COVID-19 patients was analyzed by preparation COX regression.

  **Feature**             **HR**   **95% CI**      ***P*-value**
  ----------------------- -------- --------------- ---------------
  **Model 1**                                      
  Pneumonia               3.393    0.833--13.828   0.088
   Bilateral lung         1.523    0.783--2.964    0.215
   Ground-glass opacity   2.266    1.196--4.291    0.012\*
   Reticular/linear       2.272    1,417--3.644    0.001\*
   Air bronchogram        5.807    2.338--14.421   \<0.001\*
   Consolidation shadow   8.971    4.997--16.108   \<0.001\*
  **Model 2**                                      
  Ground-glass opacity    2.096    1.102--3.985    0.024\*
  Reticular/linear        2.07     1.275--3.362    0.003\*
  Air bronchogram         4.741    1.869--12.029   0.001\*
  Consolidation shadow    8.994    4.953--16.331   \<0.001\*

*466 patients were enrolled in model 1 and model 2, since a total of 466 patients were available on CT reports. HR, hazard ratio. \*indicates p-value \<0.05*.

*Model 1: univariate preparation COX regression*.

*Model 2: multivariate preparation COX regression: Sex, age, and comorbidity were adjusted*.

Discussion {#s4}
==========

Our study was designed to analyze the clinical findings and outcomes of mild-moderate patients in one novel mobile cabin hospital in Wuhan, China. Our study found that older age, comorbidities, several lung CT features (e.g., ground-glass opacity, reticular/linear, air bronchogram, or consolidation shadow) were associated with aggravation of patients\' conditions, which indicated that patients with these characteristics should receive additional attention in mobile cabin hospitals. In addition, typical clinical symptoms showed a decreasing trend with time, which suggested that the initial symptoms of mild-moderate patients with COVID-19 may become insidious.

Several articles related to COVID-19 have revealed that most of the patients infected with SARS-CoV-2 had mild or moderate infections ([@B2], [@B6], [@B13]). These patients with mild-moderate disease could recover with general treatment, although a few patients require intensive care due to the worsening of their condition ([@B9]). However, these patients were not effectively treated or isolated due to limited medical resources in the early stages. The activities of these mild-moderate patients further aggravated the spread of the disease in the community. Therefore, several novel mobile hospitals were built to address this difficulty. From February 6th 2020 to February 20th, 869 mild-moderate patients were admitted to one of these hospitals, Wuchang Fangcang Hospital that was built within 3 days and could offer 800 beds for patients. Of the 869 patients, 70.9% recovered in the hospital, and 10.9% were transferred to the high-level designated hospital due to patients\' condition aggravation in a timely manner for further treatment. Literature has demonstrated that cabin hospitals played a critical role in the management of previous infectious disease and disasters ([@B9], [@B10]). Compared to the traditional mobile hospitals, these novel cabin hospitals had three key characteristics (rapid construction, massive scale, and low cost) and five essential functions (isolation, triage, basic medical care, frequent monitoring and rapid referral, and essential living and social engagement) ([@B14]). The earlier implementation of social distancing could obviously limit the epidemic and even reduce death ([@B15]). Interestingly, 12 days after the first fangcang hospitals started admitting patients, the number of confirmed cases in Wuhan steadily declined from Feb 18th, 2020 ([@B16]). Another study also suggested that these novel mobile cabin hospitals were characterized by flexibility and played an important role in the control of epidemic ([@B17]). Therefore, fangcang hospitals may provide inspires for other countries in COVID-19 epidemic.

Sex differences among patients infected with SARS-CoV-2 have been described ([@B18]). In our study, sex differences existed in the symptoms of COVID-19. Females had more chest tightness, dyspnea and diarrhea, and male patients had a higher rate of fatigue, muscle aches, and anorexia. However, the prognosis was not influenced by sex, although a previous study suggested that males were associated with more severe cases. This may be because patients in the hospital had mild disease on admission.

Several studies have suggested that older age and comorbidities are significantly associated with composite endpoints or death ([@B2], [@B19], [@B20]). Chest CT plays a critical role in the diagnosis and evaluation of COVID-19. The incidences of consolidation, linear opacities, crazy-paving pattern, and bronchial wall thickening in severe/critical patients were significantly higher than those of the ordinary patients ([@B21]). Our study found that relatively severe CT manifestations existed in older age patients or patients with at least one comorbidity. More patients aged 45 years or older reached the endpoint, and older age was a potential risk factor for the endpoint. However, the patients over 60 years did not have more cumulative risk than the 45--60 years group, which was not consistent with the literature reports ([@B22], [@B23]). This may be due to the age limitation of the mobile hospital that required advanced age patients, especially those with comorbidities, to be directly admitted to designated hospitals. Similarly, comorbidities may be another risk factor for the development of endpoints. In the other proportion COX regression model, results showed that several chest CT features (e.g., ground-glass opacity, reticular/linear, air bronchogram, or consolidation shadow) were associated with the poor outcome for mild-moderate COVID-19 patients. These results reminded us that patients with these risk factors should receive more attention to prevent patients\' condition aggravation. Or, the doctors should identify these patients early and transfer them to the high-level designated hospitals.

The characteristics of generational transmission may be diverse due to virus mutations. The initial symptoms of infected patients may have changed with time. One study suggested that a novel SARS-CoV-2 mutation (ORF3a) had been found in Europe and may appear to be spreading worldwide ([@B24]). Therefore, we explored the clinical dynamics in mild-moderate patients from Wuchang Mobile Cabin Hospital. Our results revealed that the typical symptoms of COVID-19, including fever, cough, fatigue, muscle aches, and anorexia, showed a decreasing trend with time. In addition, catarrhal symptoms showed an increasing trend, although the difference was not significant. The results suggested that the typical symptoms of mild-moderate patients may become insidious, especially in the later stage of epidemic. Several reasons may contribute to the trend. First, as previously described, virus mutation may be responsible for the phenomenon, although the evidence is limited. Secondly, the detection capability of SARS-CoV-2 for contacts were furtherly enhanced, which lead to the recognition of COVID-19 patients before the symptoms appeared ([@B15]). Besides, the number of new cases was gradually reduced after Feb 2nd, 2020 and the medical assistance measures were gradually boosted during this period, which gave hospitals extra capacity to deal with patients with mild symptoms or single symptoms ([@B14], [@B15]). In brief, while some factors may affect the registration of patient\'s symptoms, it may be hard for health workers to identify COVID-19 according to the symptoms. In addition, the conditions on lung CT showed an improving trend, although the outcomes of patients within 15 days of admission were not different among the groups.

Some limitations existed in our study. Laboratory tests of most patients were unavailable due to the limitations of converted hospitals. Another limitation of our study was the self-report of comorbidities on admission. In addition, only 869 patients from one mobile cabin hospital were analyzed. A larger sample size may further increase the reliability of the conclusion.

Conclusion {#s5}
==========

Older age, comorbidities and some chest CT features (e.g., ground-glass opacity, reticular/linear, air bronchogram, or consolidation shadow) were associated with poor outcomes for these mild-moderate patients. The initial symptoms of mild-moderate patients with COVID-19 may became insidious and deserve our attention.
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